Introduction {#s0005}
============

Autologous dendritic cell (DC) vaccines have been used in the past 25 years for the treatment of cancer with mixed outcomes [@bb0005]. Although good clinical responses have been reported and a DC-based vaccine has even been granted approval by the FDA for the use in advanced prostate cancer [@bb0010], the vast majority of the studies resulted in objective response rates of less than 10% with the clinical benefit generally limited to a period of about 3 months.

A number of different reasons have been suggested to explain why DC vaccines do not produce better clinical results. Among these reasons are (1) the complexity of the isolation and differentiation/maturation procedures involved in vaccine preparation (2) the variability of the antigen loading and DC maturation protocols (3) the source and type of antigen used and (4) the presence of an inflammatory immunosuppressive tumor microenvironment that cannot be overcome by the DC-based vaccine.

In this respect melanoma patients with elevated inflammatory markers such as raised LDH, lymphocyte/neutrophil ratio, C-reactive protein [@bb0015] and inflammatory cytokines such as IL-6 and IL-1ra have a generally poor prognosis and tend not to respond to treatment [@bb0020], [@bb0025].

A few years ago we completed an early phase study with autologous *ex-vivo* expanded DCs pulsed with allogeneic tumor cell lysate in patients with metastatic melanoma to assess the safety and the feasibility of this approach. We collected serial serum samples from the patients on study to evaluate panel inflammatory markers and we report the results here.

Materials and Methods {#s0010}
=====================

Clinical Trial {#s0015}
--------------

This was a phase I/II study of autologous *ex-vivo* expanded DCs pulsed with allogeneic tumor cell lysate in patients with unresectable metastatic melanoma. The study was approved by the Local Ethics Committee at St George\'s Hospital Medical School (Ethics Committee reference number: 03.0285) and the endpoints were primarily safety and feasibility. Patients with stage IV melanoma (either treatment naïve or pre-treated) with an ECOG ps 0--1, no prior therapy for 4 weeks and life expectancy greater than 3 months were considered eligible Exclusion criteria included concurrent treatment, cerebral metastases other than those stable after 3 months of treatment, abnormal renal (Creatinine \>140 μmol/L) or liver function test (Bilirubin \>1.5 × normal limit or AST/ALT/ Alk Phos \>2 × upper limit of normal), excessive tumor burden (at the physicians\' discretion).

All patients received 1-3 × 10^6^ tumor lysate-pulsed DCs intradermally at 2 weeks interval for 12 weeks and eventually monthly thereafter until radiological or clinical progression. In addition, low dose IL-2 (6MIU units daily subcutaneously for 3 days) was given after every vaccination. Disease was re-assessed every 3 months with standard imaging and responses evaluated as per RECIST 1.1. Cryopreserved vaccines were recovered from storage in liquid nitrogen by thawing in a 37°C water bath over 100 s, before being re-cultured for 24 h.

Serum Collection {#s0020}
----------------

Samples were collected up to 72 hours prior to the first vaccine and at week 4 and 12 on study prior to administration of the vaccine. Ten milliliters of blood was collected into EDTA tubes by venepuncture. Tubes were centrifuged at 2000G for 10 minutes and serum was subsequently aspirated from the cell pellet. Serum was frozen at -70°C within 1 minute of separation and stored until use.

Dendritic Cells Isolation and Differentiation {#s0025}
---------------------------------------------

One unit of peripheral blood was taken from study participants by apheresis, centrifuged to isolate the cell pellet and labeled with Clinimax CD14 beads according to the manufacturer\'s instructions (Miltenyi). Cells were isolated using the Enrichment 1.1 protocol on the Clinimax apparatus. Isolated CD14 cells were washed in phosphate buffered saline (PBS) and then differentiated using IL-4 and GM-CSF (Peprotech and Leukomax respectively). CD14+ cells were cultured in 25 ml of RPMI1640 supplemented with 5% human AB serum (Gibco) in T175 flasks at 1-2 × 10^6^ cells ml^−1^ with GM-CSF (100ngml^−1^) and IL-4 (50ngml^−1^) for 7 days. Cytokines were refreshed at day 2 and 4. On day 7, cells were harvested, washed and counted.

Tumor Lysate Preparation and DC Loading {#s0030}
---------------------------------------

Generation of monocyte-derived DCs, pulsing with tumor cell line derived lysates and freeze/thaw maturation process have been detailed elsewhere [@bb0030]. Melanoma tumor lines (KM, MJT3 and NF) were grown as previously described [@bb0035]. Melanoma cells were irradiated with 150Gy and then lysed by repeated freeze/thaw cycles. Lysates were assessed for residual cell viability using Trypan Blue staining and were passed through 0.2 μm filters to remove cell debris. Protein concentration was determined by Bio-Rad protein assay kit. Tumor lysate was stored at −80°C until used. On day 7 DCs were re-plated at 3x10^6^ cell ml^−1^, tumor lysate was added to a final concentration of 100μgml^−1^ and cells cultured for 2 hours in RPMI 1640, supplemented with 5% human AB serum (Gibco) at 37°C. IL-4 and GM-CSF were added for a further 2 hours and then cells were harvested, aliquoted and stored in liquid nitrogen for subsequent use.

Serum Biomarker Analysis {#s0035}
------------------------

Cytometric bead array was performed by Rules Based Medicine (RBM; see website for details: www.rulesbasedmedicine.com/) using their basic Human Multi-Analyte Profile (MAP) array. Briefly, a multiplex bead array system was employed to determine the levels of a number of markers, including cytokines and chemokines, present in the serum of patients. A complete list of analytes is shown in [Table 1](#t0005){ref-type="table"}.Table 1Complete list of analytes in RBM human MAP panel, used for determination of serum proteinsTable 1Alpha FetoproteinErythropoietinIL-5MyoglobinAlpha-1 AntitrypsinFactor VIIIL-6PAI-1α-2 MacroglobulinFABPIL-7PAPAdiponectinFerritinIL-8PAPP-AApolipoprotein-A-1FGF-basicIL-10SGOTApolipoprotein-CIIIFibrinogenIL-12 p40SHBGApolipoprotein-HG-CSFIL-12 p70PSA, FreeBDNFGSTIL-13RANTESβ-2 MicroglobulinGM-CSFIL-15Serum Amyloid PC Reactive ProteinGrowth HormoneIL-16Stem Cell FactorCalcitoninHaptoglobinIL-18TBGCancer Antigen 19--9ICAM-1InsulinThrombopoietinCancer Antigen 125IFN-gammaLeptinTIMP-1CEAIgALipoprotein (a)Tissue FactorCD 40IgELymphotactinTNF-αCD40 LigandIGF-1MCP-1TNF-βComplement 3IgMMDCTNF RIICK-MBIL-1αMIP-1αTSHEGFIL-1βMIP-1βVCAM-1ENA-78IL-1raMMP-2VEGFEndothelin-1IL-2MMP-3vWFENRAGEIL-3MMP-9EotaxinIL-4Myeloperoxidase

The concentration of Apolipoprotein E3 (ApoE3) in sera was measured with an in-house ELISA. Ninety-six-well NUNC maxisorp microtitre plates were coated with 50 μl/well of 1 μg/ml rat anti-human ApoE3 (MAB41441, R & D Systems, UK) in PBS overnight at 4°C. The plates were washed 4 times with PBS containing 0.05% Tween (PBS-T) and then blocked with 300 μl/well PBS containing 1% bovine serum albumin (BSA, Sigma, UK) for 1 hour at room temperature. After 4 washes with PBS-T, 50 μl/well human recombinant ApoE3 standard (4144-AE, R & D Systems, UK) diluted serially from 1000 to 0.1 ng/ml and human serum samples diluted 1/1000 (all in PBS containing 1% BSA) were added to the plates in triplicate and incubated for 2 hours at room temperature. After 4 washes with PBS-T, 50 μl/well goat anti-human Apo E (AF4144, R & D Systems, UK) diluted to 1 μg/ml was added and incubated overnight at 4°C. After 4 washes with PBS-T, 50 μl/well rabbit anti-goat IgG-HRP (R & D Systems, UK) at 1/1000 was added and incubated for 30 minutes at room temperature. The plates were washed a further 4 times with PBS-T and 2 times with 0.05 M phosphate--citrate-buffer (pH 5.0) before developing with 100 μg/ml 3,3′,5,5′-tetramethylbenzadine dihydrochloride in phosphate--citrate-buffer (pH 5.0) containing 0.006% H~2~O~2~. Finally, the reaction was stopped with 12.5 μl/well 1 N H~2~SO~4~ and the optical densities of the wells were read at 450 nm with an ELx800 microplate reader (Bio-Tek, UK). The coefficients of variance for interplate and interday variation of this ELISA were 4.2% and 4.6% respectively. The levels of serum MiP-1α and ICAM-1 were measured using commercial kits (DY270 DuoSet and DY720 DuoSet respectively, R & D Systems, UK) according to the manufacturer\'s instructions.

Statistical analysis {#s0040}
--------------------

The data were analyzed using Prism research software with Student\'s *t*-test or Mann--Whitney *U* test, dependent on normality. A *P* value \<0.05 was considered statistically significant.

Progression-free survival (PFS) was calculated from time of enrolment until disease progression or death/last follow-up. Overall Survival (OS) was calculated from time of enrolment to death or last follow-up. Kaplan--Meier analysis was used to estimate PFS and OS. The log rank test assessed differences in progression or survival in patients with different immunological or clinical parameters.

Results {#s0045}
=======

Clinical Outcomes {#s0050}
-----------------

Twenty-two patients (21 male and one female) were enrolled in the study ([Table 2](#t0010){ref-type="table"}). Patients received a median of 6 vaccines (range 1--12) with no significant local or systemic toxicity. Twenty-one patients were evaluable for response. One patient discontinued treatment before radiological disease re-assessment. Four out of the 21 (19%) patients evaluable experienced an objective response as per RECIST 1.1 criteria. Two patients achieved a complete response (CR) and they are still alive at time of writing with an estimated overall survival of about 80 months for both. Seven patients had a stability of disease (SD). For five of these patients the disease remained stable for a period of 6 months or more for a total calculated clinical benefit (CB = CR + PR + SD ≥ 6 months) of 43% (9/21).Table 2Patients\` CharacteristicsTable 2Age/GenderStage AJCC v.7ECOG PSBORTreatment-naivePFS (months)OS (months)64 maleIVb0SDNo718 months50 maleIVc0CRYes85 months - Alive85 months - Alive75 maleIVa0PRYes2480 months -- Alive38 maleIVc1SDNo638 months48 maleIVc0SDYes618 months60 maleIVc0SDNo610 months45 maleIVc0PRYes1675 months50 maleIVb0SDNo714 months30 maleIVc0CRNo81 months - Alive81 months - Alive53 maleIVb0SDNo4 months16 months73 maleIVb1SDYes4 months15 months60 maleIVa0PDYes3 months11 months55 maleIVa0PDNo3 months10 months67 maleIVa0PDNo3 months4 months49 femaleIVa0PDNo3 months10 months49 maleIVc1PDYes3 months7 months70 maleIVa0PDNo3 months7 months74 maleIVa0PDYes3 months5 months70 maleIVc1PDYes3 months3 months60 maleIVc0PDNo5 months5 months54 maleIVb0PDNo4 months4 months63 maleIVa1NEYesNENE[^1]

Upon closure of the trial, patients were retrospectively stratified into non-responder and responder based on the CB. Responders showed a significantly longer PFS (HR 0.23; 95% CI 0.08--062; *P* \< .001) and OS (HR 0.22; 95% CI 0.08--0.59; *P* \< .001; [Figure 2](#f0010){ref-type="fig"}). At the time of writing, 0/12 of the non-responders have survived however 3/9 of the responder group are alive.

Serum Protein Analysis: Pre-Vaccination Differences in Responders and Non-Responders {#s0055}
------------------------------------------------------------------------------------

Pre-vaccination serum samples from the 12 clinically non-responding patients and 9 responding patients were quantified by means of a multiplex approach. We have analyzed 90 different serum proteins ([Table 1](#t0005){ref-type="table"}) and results from the two different cohorts were compared.

We detected significant pre-vaccination differences between the non-responder population and the responder population for six proteins ([Figure 1](#f0005){ref-type="fig"}). Apolipoprotein C111 (86.2 μgml^−1^ vs. 48.8 μgml^−1^; *P* = .05), IL-12 p40 (0.12 ngml^−1^ vs. 0.02 ngml^−1^; *P* = .02), MiP1α (68.4 pgml^−1^ vs. 52.1 pgml^−1^; *P* = .04), stem cell factor (259.8pgml^−1^ vs. 210.4pgml^-1;^ P = .02) and TNFα (6.1 pgml^−1^ vs. 2.4 pgml^−1^; *P* = .03) levels were significantly increased in the non-responder group compared to the responders. In contrast to the elevation of these pro-inflammatory mediators seen in the non-responsive group of patients, a significant decrease in Lipoprotein A in the non-responders compared to responders (72.3 μgml^−1^ vs. 163.2 μgml^−1^; *P* = .05) was observed. (See [Fig. 4](#f0020){ref-type="fig"}.)Figure 1Pre-vaccination serum protein differences between responders (n = 9) and non- responders (n = 12). Figure shows mean and standard deviation. p values are student\'s t-test for normal data and Mann--Whitney for non-normal data.Figure 1Figure 2Kaplan--Meier estimates of PFS and OS of responders (N = 9) vs. non-responders (N = 12).Figure 2Figure 3Confirmatory serum analyte quantification determined by ELISA and Apolipoprotein E. Statistical tests are non-paired parametric (Student\'s *t*-test) or non-parametric (Mann--Whitney *U*), dependent on normality of data.Figure 3Figure 4Kaplan--Meier estimates of PFS and OS of patients with higher (N = 10) vs. lower serum level (N = 11) of ApoE.Figure 4

No significant differences were observed between responders and non-responders for serum samples obtained at weeks 4 and 12. No significant changes were observed between baseline and samples at week 4 and 12.

Validation of Markers Using ELISA and Predictive Techniques {#s0060}
-----------------------------------------------------------

Since the low study numbers preclude the use of type 1 error correction in the cytometric bead data, we sought to identify additional methods to validate these data. Initially we used a powerful literature search software (Pathway studio) to develop a network of connectivity between the potential markers identified and then we attempted to find additional molecules that would fit into this network. These approaches led to the identification of ApoE as a putative additional marker. ApoE was quantified by ELISA and, as predicted, a significant difference between the non-responder and responder patients was observed (129.6 μg/ml responders vs. 201.5 μg/ml non-responders; *P* = .005; [Figure 3](#f0015){ref-type="fig"}). MiP1α and ICAM-1 were added as controls and ELISA data confirmed the original observations (MiP1α 42.0 pg/ml responders vs. 134.1 pg/ml non-responders; *P* = .03; ICAM 258.6 ng/ml responders vs. 286.9 ng/ml non-responders; *P* \> .05; [Figure 3](#f0015){ref-type="fig"}). It must be noted that the ELISA and RBM microarray results differ in magnitude suggesting differences in the sensitivity of the two assays.

The mean value of ApoE observed in this cohort of subjects was selected to categorize patients as higher or lower ApoE serum level. Patients with levels of ApoE above the average had a significantly shorter PFS (HR 3.02; 95% CI 1.09--8.35; *P* = .015) and OS (HR 2.40; 95% CI 0.9--6.3; *P* = .034). No differences were observed for MiP1α.

Neutrophil/lymphocyte Ratio and LDH {#s0065}
-----------------------------------

No significant differences were observed in the neutrophil/lymphocyte ration and LDH levels over time nor between responders and non-responders (data not shown).

Discussion {#s0070}
==========

Despite that the majority of patients do not gain any benefit from DC vaccines, this approach has occasionally given rise to dramatic responses in melanoma. Biomarkers are crucial to identify which patients are more likely to respond to DC vaccines. We looked for correlations between pre- or post- vaccination biomarkers and clinical outcomes to DC therapy in a cohort of patients with stage IV melanoma receiving an autologous DC vaccine. We have identified a general inflammatory marker profile and we validated the data using literature-searching software to predict for additional markers, which would be expected to be elevated if the original data is correct. We thus identified ApoE as an additional biomarker of non-response and we have subsequently confirmed this by ELISA.

ApoE has been the focus of intense interest with regard to immunomodulation as well as cancer for more than three decades. Despite that, there is still a lack of consensus on the role of ApoE in various cancers, overexpression of ApoE resulting in elevated levels in the serum, plasma or urine is associated with a poor prognosis or advanced stage in human cancers, including lung [@bb0040], [@bb0045], [@bb0050], gastric [@bb0055], [@bb0060], ovarian [@bb0065], [@bb0070] and bladder cancer [@bb0075], [@bb0080]. On the contrary, ApoE was also shown to act as a direct metastasis-suppressive factor in melanoma [@bb0085], identifying ApoE as a potential biomarker for assessing tumor stage, metastasis, prognosis or response to treatment. Van den Elzen et al. proposed a pro-inflammatory role of ApoE, showing ApoE involved in the presentation of CD1a-loaded lipid antigens by antigen presenting cells (APC) for recognition by natural killer T (NKT) cells, which in turn respond by secreting cytokines (e.g. IFN-γ) and initiating an immune response [@bb0090]. A pro-inflammatory role of ApoE could also be due to its association with cell lipid homeostasis. ApoE possess lipophilic properties, potentially removing cholesterol and other lipids from the cell membrane and consequently initiating the recruitment of TLRs to lipid drafts as a possible signal of cell damage [@bb0095]. As a result, transcriptional factors, such as NF-κB and interferon regulatory factors (IRFs) are activated and contribute to the production of pro-inflammatory cytokines [@bb0100], [@bb0105]. Combined with additional markers, such as those identified in this study, measurement of ApoE could identify inappropriate inflammation in patients prior to treatment and thus identify patients who are most unlikely to benefit from DC immunotherapy.

Inflammation in cancer may be caused by tumor invasion and this perturbation of homeostasis could generate a sterile inflammatory response [@bb0110]. Intuitively inflammation would seem to be prerequisite for activation of the immune response and the generation of an anti-tumor outcome. However, chronic inflammation has a negative correlation with cancer outcomes [@bb0115], [@bb0120]. The immune response status at the time of diagnosis may have a bigger impact on prognosis than the typical staging procedures irrespective of other treatments given [@bb0125].

One possible mechanism for the influence of inflammation on cancer is the shift between a desirable Th1 (cell mediated immunity associated) response and a non-effective Th2 (humoural immunity associated) response [@bb0130]. If this were the case, then one clinical possibility would be to pre-treat patients about to undergo immunotherapy with an anti-inflammatory protocol.

It is interesting to note that there are several reports, which have observed an improved response to vaccination in mice when they have been pre-treated with known anti-inflammatories. At present, the strongest evidence available that confirms pre-treating is beneficial has been shown with Lenalidomide [@bb0135], [@bb0140]. This was subsequently confirmed in humans with multiple myeloma patients who responded to Prevnar after they had been pre-treated with Lenalidomide [@bb0145]. Although Lenalidomide has been reported as having a co-stimulatory function, it is also a strong inhibitor of inflammation through the Cox-2 pathways [@bb0150]. Hence, a pre-immunotherapy course of anti-inflammatory treatment might render the potentially unresponsive patient clinically responsive. In this study we have described a panel of potential inflammatory markers that can help to identify patients less likely to response to a DC-vaccine. Other groups have looked at larger cohorts of patients treated with PD-1 inhibitors or high dose IL-2 and they have detected similar biomarkers. In keeping with our findings, they are present prior to treatment and rather than as a result of treatment, they are elevated in non-responders and include many markers of chronic inflammation as described here [@bb0155], [@bb0160].

Conclusions {#s0075}
===========

In summary, our findings support the notion that treating the inflammatory background may have an impact on clinical outcome for patients receiving immunotherapy. A larger study is needed to confirm the significance of ApoE as a predictive biomarker for response to DC vaccines.
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[^1]: BOR: Best Overall Response, SD: Stable Disease, PR Partial Response, CR Complete Response, PD Progressive Disease; PFS: Progression-free survival, OS: Overall Survival; NE; not-evaluable.
